Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a consensus recommendation of “Moderate Buy” by the eighteen analysts that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $52.81.

Several equities analysts have recently weighed in on the company. Oppenheimer decreased their price objective on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Monday, November 11th. Canaccord Genuity Group reiterated a “buy” rating and issued a $90.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, November 19th. Royal Bank of Canada restated an “outperform” rating and set a $54.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Barclays reduced their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Finally, Chardan Capital increased their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research note on Monday, November 18th.

Intellia Therapeutics Stock Down 15.1 %

Intellia Therapeutics stock opened at $10.20 on Friday. Intellia Therapeutics has a twelve month low of $9.93 and a twelve month high of $34.87. The company has a 50 day moving average of $13.77 and a 200-day moving average of $18.96. The stock has a market capitalization of $1.04 billion, a PE ratio of -1.87 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter last year, the company posted ($1.38) EPS. Equities analysts anticipate that Intellia Therapeutics will post -5.12 EPS for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 28,735 shares of company stock valued at $349,909. Company insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC lifted its position in shares of Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after buying an additional 1,550 shares during the last quarter. Eastern Bank bought a new position in shares of Intellia Therapeutics in the third quarter worth about $41,000. Values First Advisors Inc. acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at approximately $54,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after purchasing an additional 794 shares during the last quarter. Finally, KBC Group NV increased its position in Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after purchasing an additional 1,020 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.